News
Academy
Publications
Media
Conferences
Columns
Resources
Webcasts
Subscribe

|Podcasts|July 16, 2013

What does RBM mean to Sanofi's CRAs and site monitors

Lori Convy, Assistant Director, Clinical Research Monitoring, Sanofi discusses what risk-based monitoring mean to Sanofi's CRAs and site monitors?

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Content

Unlock Commercial Growth through Data-Driven Patient and HCP Insights Podcast

May 2nd 2025

Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit

February 7th 2025

Thinking Big for Small and Mid-Sized Biotechs: How Applying Modeling and Simulation Technologies Can Improve Drug Development

January 6th 2023

The Evolving Relationship Between Sponsors and the Contract Research Organizations

December 8th 2022

The MDR: Navigating Europe’s New Standard for Medical Device Safety

October 25th 2022

Trending on Applied Clinical Trials Online

2026 DIA Global Annual Meeting: Why Protocol Digitization Has Been So Hard to Automate—Until Now

2026 DIA Global Annual Meeting: What Drives Sponsors to Mixed Outsourcing Models and What the Transition Looks Like

Tapping the Global Potential of China’s Biotech Surge

2026 DIA Global Annual Meeting: What the FDA's Real-Time Data Push Actually Means for Sponsors and CROs

ACT Brief: Real-Time Data Harmonization Infrastructure, Modern Trial Payments, and SCLC Drug Confirmatory Failure